Rana Mckay, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Non-urology Healthcare Related)
    Ineligible company: 
    Bayer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Novartis
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Exelixis
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Janssen
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Non-urology Healthcare Related)
    Ineligible company: 
    BMS
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Non-urology Healthcare Related)
    Ineligible company: 
    Tempus
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Aveo
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Calithera
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Telix
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    SeaGen
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023

Pages

Return to Treatment for Hormone Sensitive Prostate Cancer (2023)